Oncology Main Article


Daiichi Sankyo Cancer Enterprise

Daiichi Sankyo Cancer Enterprise

The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking in order to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do.

World-Class Science Organization

The Daiichi Sankyo Cancer Enterprise is committed to becoming a world-class science organization. Our team’s exceptional scientific attitude results in outstanding medicinal chemistry, antibody engineering and discovery biology.

Dynamic and Sustainable R&D Engine

The Daiichi Sankyo Cancer Enterprise portfolio is powered by our research engines:

  • Two laboratories for biologic/immuno-oncology and small molecules in Japan
  • Plexxikon Inc. – small molecule structure-guided R&D center in Berkeley, California

7 New Molecular Entities by 2025

Anchored by three pillars including our investigational Antibody Drug Conjugate Franchise, Acute Myeloid Leukemia Franchise and Breakthrough Science, the Daiichi Sankyo Cancer Enterprise aims to deliver seven distinct new molecular entities over eight years during 2018 to 2025.

Enhanced Capabilities Through Collaboration

To complement and expand our premier cadre of internal scientists, we are collaborating with leading academic and business partners to leverage cutting-edge science in new treatment modalities, disease biology, diagnostics and pipeline prioritization.

The agents discussed on the website are investigational and have not been approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Safety and efficacy have not been established.


ADC Franchise More Stories Content

More Stories

ADC Franchise

The investigational Antibody Drug Conjugate (ADC) Franchise of the Daiichi Sankyo Cancer Enterprise is built around our proprietary DXd ADC technology, which is being researched across multiple types of cancer. Our proprietary linker and payload technologies have been specifically designed to potentially address various limitations of two critical components of an ADC: the payload and linker

read more ...